financetom
Business
financetom
/
Business
/
What's Going On With Vaccinex Stock Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Vaccinex Stock Wednesday?
Sep 22, 2024 12:19 AM

Vaccinex, Inc. ( VCNX ) shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock.

What To Know: The company announced the immediate exercise of outstanding warrants to purchase 1,067,492 shares for $5.36 per share. As a result, the company will issued 827,483 shares and the pre-funding of 240,009 shares.

Also, Exercising warrant holders will receive new warrants to purchase shares for an additional $0.125 per new warrant.

How To Buy Vaccinex Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Vaccinex ( VCNX ) 's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Related Link: Bitcoin, Ethereum, Dogecoin Pump 5%: Here’s What Wednesday’s Fed Rate Cut Decision Could Mean For Crypto

VCNX Price Action: At the time of publication, Vaccinex ( VCNX ) stock is trading 14.2% lower at $5.15, according to data from Benzinga Pro.

Image: Pexels/ Tima Miroshnichenko

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Core Natural Resources Q4 Earnings, Revenue Decline
Core Natural Resources Q4 Earnings, Revenue Decline
Feb 20, 2025
07:09 AM EST, 02/20/2025 (MT Newswires) -- Core Natural Resources ( CNR ) reported Q4 earnings Thursday of $1.04 per diluted share, down from $5.05 a year earlier. Two analysts polled by FactSet expected $2.68. Revenue and other income for the quarter ended Dec. 31 was $595.3 million, compared with $649.4 million a year earlier. Two analysts surveyed by FactSet...
Freshpet Q4 Earnings, Net Sales Rise; 2025 Outlook Set
Freshpet Q4 Earnings, Net Sales Rise; 2025 Outlook Set
Feb 20, 2025
07:03 AM EST, 02/20/2025 (MT Newswires) -- Freshpet ( FRPT ) reported Q4 earnings Thursday of $0.36 per diluted share, up from $0.31 per share a year earlier. Analysts polled by FactSet expected $0.36 per share. Net sales for the quarter ended Dec. 31 were $262.7 million, compared with $215.4 million a year earlier. Analysts surveyed by FactSet expected $264.1...
AstraZeneca to buy FibroGen's China unit for $160 million
AstraZeneca to buy FibroGen's China unit for $160 million
Feb 20, 2025
Feb 20 (Reuters) - AstraZeneca ( AZN ) will buy U.S. biotech firm FibroGen's ( FGEN ) China unit for about $160 million, in its latest deal to boost its presence in the country despite growing US-China trade tensions. Fibrogen ( FGEN ) said the deal will give AstraZeneca ( AZN ) full rights to its anemia drug roxadustat in...
Springworks Therapeutics Q4 Net Loss Narrows
Springworks Therapeutics Q4 Net Loss Narrows
Feb 20, 2025
07:00 AM EST, 02/20/2025 (MT Newswires) -- Springworks Therapeutics ( SWTX ) reported a Q4 net loss Thursday of $1.04 per share, narrowing from a net loss of $1.44 a year earlier. Analysts polled by FactSet expected a loss of $0.71. Net product revenue for the quarter ended Dec. 31 was $61.5 million. The previous year's numbers were not provided....
Copyright 2023-2026 - www.financetom.com All Rights Reserved